Purespring Therapeutics, a pioneering gene therapy company focused on transforming kidney disease treatment, has raised £80 (€96m) in an oversubscribed Series B round. Led by Sofinnova Partners, this funding also drew support from Gilde Healthcare, Forbion, British Patient Capital, and Syncona Limited.
Cancer UK/UCB collaboration: study with 2nd compound started
Latest NewsBelgian UCB SA and British Cancer UK have started a second clinical study within their multi-year partnership to evaluate the safety and tolerable dose of UCB4594 in patients with advanced cancers.
Agomab raises US$89m in Series D
Latest NewsAnother strong financing round for Belgian Agomab NV. Sanofi is joining the band wagon of targeting the TGFbeta receptor.
Sustainable Ultra-Low Freezing with the U701V
Sponsored PublicationsUltra-low freezers are playing a key role in biomedical research as they are required to store very temperature-sensitive biologicals such as DNA, enzymes and more, but they have high energy demands. Recognizing these issues, B Medical Systems has introduced the U701V, a new ULT freezer that balances energy efficiency with exceptional performance.
Rentschler with double-digit investment in Germany
Latest NewsRentschler Biopharma announces largest single investment in the higher double-digit range at its headquarters in Germany for construction of a new buffer media facility in Laupheim.
Roche leaves Alzheimer partnership with UCB
Latest NewsRoche drops a third Alzheimer’s candidate this year, leaving a partnership with UCB just four years after agreeing to work together on new treatments for the neurological disease.
Sustainable, automated, ULT storage
Sponsored PublicationsThe volume of samples and drug products requiring -80°C storage continues to increase, and shows no sign of slowing down. For many organisations, meeting these growing ULT storage requirements is challenging. The sheer volume of samples necessitates extensive storage capacity, which demands significant space, substantial energy use, and intensive management. Centralising and automating sample storage can provide a comprehensive solution.
Pichia protein production
BackgroundRecombinant protein production in Pichia typically relies on AOX1 promoter-driven expression using methanol for induction. However, some companies avoid methanol due to safety concerns or operational demands. VALIDOGEN’s unique AOX1 promoter variants enable methanol-free protein production at high space-time yields, offering advantages beyond safety. Latest case studies underscore the strength of this technology.
Nuclera Secures US$75m to Advance Protein Discovery System
Latest NewsBiotech firm Nuclera raises $75M to expand its cutting-edge protein discovery system, speeding up breakthroughs in labs worldwide.
Purespring bags £80m to transform kidney disease treatment
Latest NewsPurespring Therapeutics, a pioneering gene therapy company focused on transforming kidney disease treatment, has raised £80 (€96m) in an oversubscribed Series B round. Led by Sofinnova Partners, this funding also drew support from Gilde Healthcare, Forbion, British Patient Capital, and Syncona Limited.
SciVario® twin Bioprocess Controller: Addressing Current and Future Needs
ProductsEfficiency and flexibility are key factors to stay competitive in the bioprocess field. With this aim in mind, the SciVario twin was envisioned as a tool to save time and costs during process development and optimization. All critical process parameters can be precisely controlled directly at the controller’s touch screen. The device is suitable for microbial and cell culture applications in both glass and single-use bioreactors. The innovative bay-drawer system enables flexible adaptation to unique requirements and changing processes. Frequent updates offered by Eppendorf, such as new functional modules, support for different bioreactor sizes and models, as well as additional software features, will help to enable the SciVario twin to serve your current and future bioprocessing needs.